We and others have found a significant association of rare H-ras VNTR alleles with breast cancer, however, the biological mechanism underlying this relationship remains unclear. Two hypotheses can explain this association. The first is that rare H-ras VNTR alleles are caused by a mutation in another critical gene and are therefore markers of genomic instability, but are not directly responsible for the inherited susceptibility to cancer. The second possibility is that rare alleles directly participate in carcinogenesis via their transcriptional enhancer effects. The studies proposed here are aimed at distinguishing between these two alternate hypotheses. Our recent minisatellite variant repeat (MVR) analyses of the H-ras VNTR show that most rare alleles are characterized by aberrant internal sequences suggestive of DNA rearrangements. Using technology developed in the Garrett study population, we will further explore the relationship of H-ras rare alleles to genetic instability, both in the germline and in tumors, in the larger population of the Carolina Breast Cancer Study (CBCS). We will determine the association of germline H-ras rare alleles with the presence of genetic instability in breast tumors, as measured by microsatellite instability and gene amplification, the inter-generational stability of the H-VNTR both in CEPH pedigrees and in relatives of CBCS breast cancer patients with rare alleles, interactions between H-ras rare alleles and potential epidemiologic and environmental factors for breast cancer and modification by rare H-ras alleles of the risk for breast cancer associated with the known cancer susceptibility genes, BRCA1 and MSH2. In order to determine whether the H-ras VNTR plays a direct role in the development of breast cancer, we will evaluate the putative function of this region as a transcriptional enhancer, determine whether the regulatory effects are mediated by NF-kappaB transcription factors, and determine if rare H-ras alleles have abnormal regulatory functions as compared with their common progenitor alleles. We will also determine whether common alleles are preferentially deleted in breast tumors which exhibit loss of heterozygosity since this would support a direct role for this region in the carcinogenic process. Finally, we will expand our repertoire of molecular techniques to more fully characterize the H-ras VNTR for both length and internal structural variation. By increasing our level of detection of 5' sequences and by developing 3' MVR methodologies, we will obtain complete MVR sequence for the entire length of each allele, thus ensuring that all variant/rare alleles are detected, especially those which arose by recombination.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058223-08S2
Application #
6483393
Study Section
Project Start
1999-08-05
Project End
2001-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
2001
Total Cost
$168,504
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820
Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Butler, Eboneé N; Bensen, Jeannette T; Chen, Mengjie et al. (2018) Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. Cancer Epidemiol Biomarkers Prev 27:67-74
Echavarria, Isabel; López-Tarruella, Sara; Picornell, Antoni et al. (2018) Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res 24:1845-1852

Showing the most recent 10 out of 598 publications